Your search

Abstract The four previous articles in this series addressed the myths and facts surrounding lipoedema. We have shown that there is no scientific evidence at all for the key statements made about lipoedema – which are published time and time again. The main result of this “misunderstanding” of lipoedema is a therapeutic concept that misses the mark. The patient’s real problems are overlooked. The national and especially the international response to the series, which can be read in both German and English, has been immense and has exceeded all our expectations. The numerous reactions to our articles make it clear that in other countries, too, the fallacies regarding lipoedema have led to an increasing discrepancy between the experience of healthcare workers and the perspective of patients and self-help groups, based on misinformation mostly generated by the medical profession. Parts 1 to 4 in this series of articles on the myths surrounding lipoedema have made it clear that we have to radically change the view of lipoedema that has been held for decades. Changing our perspective means getting away from the idea of “oedema in lipoedema” – and hence away from the dogma that decongestion is absolutely necessary – and towards the actual problems faced by our patients with lipoedema. Such a paradigm shift in a disease that has been described in the same way for decades cannot be left to individuals but must be put on a much broader footing. For this reason, the lead author of this series of articles invited renowned lipoedema experts from various European countries to discussions on the subject. Experts from seven different countries took part in the two European Lipoedema Forums, with the goal of establishing a consensus. The consensus reflects the experts’ shared view on the disease, having scrutinized the available literature, and having taken into account the many years of clinical practice with this particular patient group. Appropriate to the clinical complexity of lipoedema, participants from different specialties provided an interdisciplinary approach. Nearly all of the participants in the European Lipoedema Forum had already published work on lipoedema, had been involved in drawing up their national lipoedema guidelines, or were on the executive board of their respective specialty society. In this fifth and final part of our series on lipoedema, we will summarise the relevant findings of this consensus, emphasising the treatment of lipoedema as we now recommend it. As the next step, the actual consensus paper “European Best Practice of Lipoedema” will be issued as an international publication. Instead of looking at the treatment of oedema, the consensus paper will focus on treatment of the soft tissue pain, as well as the psychological vulnerability of patients with lipoedema. The relationship between pain perception and the patient’s mental health is recognised and dealt with specifically. The consensus also addresses the problem of self-acceptance, and this plays a prominent role in the new therapeutic concept. The treatment of obesity provides a further pillar of treatment. Obesity is recognised as being the most common comorbid condition by far and an important trigger of lipoedema. Bariatric surgery should therefore also be considered for patients with lipoedema who are morbidly obese. The expert group upgraded the importance of compression therapy and appropriate physical activity, as the demonstrated anti-inflammatory effects directly improve the patients’ symptoms. Patients will be provided with tools for personalised self-management in order to sustain sucessful treatment. Should conservative therapy fail to improve the symptoms, liposuction may be considered in strictly defined circumstances. The change in the view of lipoedema that we describe here brings the patients’ actual symptoms to the forefront. This approach allows us to focus on more comprehensive treatment that is not only more effective but also more sustainable than focusing on the removal of non-existent oedema. , Zusammenfassung Die Mythen und Fakten des Lipödems waren das Thema der vergangenen 4 Teile dieser Artikelserie. Wir konnten zeigen, dass für die zentralen – und immer wieder publizierten – Statements zum Lipödem keinerlei wissenschaftliche Evidenz vorliegt. Wesentliche Folge dieses „Fehlverständnisses“ der Erkrankung Lipödem ist ein Therapiekonzept, welches an den tatsächlichen Beschwerden der Patientinnen weitgehend vorbeigeht. Der nationale, aber vor allem auch der internationale Zuspruch, der auch in Englisch zu lesenden Reihe, war immens und übertraf all unsere Erwartungen. Die zahlreichen Reaktionen auf unsere Artikelserie machten eines deutlich: Auch in anderen Ländern führen die Stilblüten des Lipödems zu einer zunehmenden Diskrepanz zwischen den Erfahrungen der Behandler und der durch – meist ärztlich verursachten – Fehlinformation geleiteten Perspektive der Patientinnen und Selbsthilfegruppen. Die Teile 1 bis 4 der Artikelserie über die Mythen des Lipödems haben deutlich gemacht, dass wir diese seit Jahrzehnten tradierte Perspektive auf die Erkrankung Lipödem verändern müssen. Veränderung der Perspektive heißt: Weg vom „Ödem im Lipödem“, damit auch weg vom Dogma der notwendigen „Entstauung“ und hin zu den tatsächlichen Beschwerden unserer Lipödem-Patientinnen. Ein solcher Paradigmenwechsel eines seit Jahrzehnten auf immer gleiche Weise beschriebenen Krankheitsbildes kann nicht Aufgabe Einzelner sein, sondern muss auf breite Füße gestellt werden. Aus diesem Grund hat der ärztliche Erstautor dieser Artikelreihe renommierte Lipödem-Experten aus verschiedenen europäischen Ländern zu einer Diskussion über das Lipödem eingeladen. Ziel der beiden „European Lipoedema-Foren“, an denen Experten aus 7 Ländern teilnahmen, war die Erstellung eines Konsensus. Dieser Konsensus spiegelt unter Sichtung der zur Verfügung stehenden wissenschaftlichen Literatur – bei gleichzeitiger Berücksichtigung der jeweils langjährigen klinischen Arbeit mit diesen Patientinnen – die gemeinsame Sicht der beteiligten europäischen Experten auf diese Erkrankung wider. Der Komplexität des Krankheitsbildes Lipödem angemessen war auch die Struktur der Teilnehmer interdisziplinär. Nahezu alle Teilnehmer des European Lipoedema-Forum haben in der Vergangenheit entweder über das Lipödem publiziert bzw. an ihren nationalen Lipödem-Leitlinien mitgearbeitet oder sind in Vorständen ihrer Fachgesellschaften vertreten. In diesem fünften und letzten Teil unserer Artikelserie über das Lipödem sollen vorab die wesentlichen Ergebnisse dieses Konsensus kurz zusammengefasst werden, wobei der Fokus auf der empfohlenen Therapie des Lipödems liegt. Das eigentliche Konsensus-Papier, „European Best Practice of Lipoedema“, wird dann in einem zweiten Schritt im Rahmen einer internationalen Publikation veröffentlicht. Statt einer Ödem-Behandlung wird im Konsensus-Papier auf die Behandlung des Weichteilschmerzes ebenso fokussiert wie auf die psychische Vulnerabilität der Lipödem-Patientin. Zusammenhänge zwischen der Schmerzwahrnehmung und der psychischen Situation der Patientin werden anerkannt und gezielt behandelt. Hierbei wird auch das Problem der Selbstakzeptanz thematisiert und spielt im neuen Behandlungskonzept eine herausragende Rolle. Eine weitere Therapiesäule stellt die Adipositas-Behandlung dar. Adipositas wird somit als mit Abstand häufigste Begleiterkrankung – und wesentlicher Trigger – des Lipödems akzeptiert. Bei schwer adipösen Lipödem-Patientinnen sollte daher auch die bariatrische Operation erwogen werden. Kompressionstherapie und gezielte Bewegungsaktivität wurden von der Expertengruppe deutlich aufgewertet, da durch die nachgewiesenen antiinflammatorischen Effekte die Beschwerden der Patienten direkt verbessert werden. Durch ein individualisiertes Selbstmanagement werden den Patientinnen Tools mit an die Hand gegeben, die den Therapieerfolg nachhaltig stabilisieren. Sollte die konservative Therapie zu keiner relevanten Beschwerdebesserung führen, kann die Liposuktion unter Einhaltung klar definierter Vorgaben erwogen werden. Die hier beschriebene Veränderung der Perspektive auf das Lipödem stellt die tatsächlichen Beschwerden der Patientinnen in den Fokus. Dies ermöglicht eine umfassendere, damit bessere und auch nachhaltigere Behandlung als die Fokussierung auf ein nie nachgewiesenes Ödem und dessen Entstauung.

Lipedema is a chronic and progressive disease of adipose tissue caused by abnormal fat accumulation in subcutaneous tissue. Although there is no known cure for lipedema, possible complications can be prevented with conservative and surgical treatments. One of the conservative treatment options is physiotherapy and rehabilitation (PR). When the literature is examined, few studies focusing on the efficacy of PR were found for this patient group. The purpose of this review is to provide a better understanding of the effectiveness of PR applications by compiling existing studies. A bibliographic PubMed search was performed for published studies regarding PR in lipedema management in June 2019 including the last 58 years (1951-2019). Articles were chosen by reading the abstracts and subsequently data were analyzed by reading the entire text through full-text resources. A total of 15 studies met inclusion criteria. Results document how lipedema patients are benefited by PR and the effectiveness of different types of PR programs. The current review also showed that complex decongestive physiotherapy, gait training, hydrotherapy, aerobic exercise, and resistance exercise training each have value in the management of lipedema. The effects of PR for the treatment of lipedema are variable among studies, although overall PR seems to be effective in lipedema management. Although physiotherapy applications have a potentially important role in the management of lipedema, they should be used in combination with other treatment modalities. More studies with higher quality are needed to fully demonstrate the effect and efficacy of PR in lipedema patients.

Lipedema can cause chronic pain and increases patients’ risk for conditions such as lymphedema and venous disease. This author explores how lipedema affects the body, why its effects are disproportionate in the lower body, and how to diagnose and manage the condition.

Obesity is a leading cause of cardiovascular diseases and cancer. Body mass is regulated by the balance between energy uptake and energy expenditure. The etiology of obesity is determined by multiple factors including genetics, nutrient absorption, and inflammation. Lymphatic vasculature is starting to be appreciated as a critical modulator of metabolism and obesity. The primary function of lymphatic vasculature is to maintain interstitial fluid homeostasis. Lymphatic vessels absorb fluids that extravasate from blood vessels and return them to blood circulation. In addition, lymphatic vessels absorb digested lipids from the intestine and regulate inflammation. Hence, lymphatic vessels could be an exciting target for treating obesity. In this article, we will review our current understanding regarding the relationship between lymphatic vasculature and obesity, and highlight some open questions.

Lipedema is a chronic, progressive, painful, increased deposition subcutaneous fat tissue in women with a clear disproportion between the trunk and extremities. Lipedema offen lead to oedema, which are worsened by orthostasis, and hematoma after minor injury. The pathogenesis is unknown and no curative treatment is available. Conservative therapy consisting of lymphatic drainage and compression stockings is often recommended, but is only effective against the edema component. Some patients show a short-term improvement when treated in this way. Permanent reduction of the pathological subcutaneous fat on the legs and arms has become possible by employing advanced liposuction techniques using microcannula technology in local tumescent anaesthesia.

Genetic or acquired defects of the lymphatic vasculature often result in disfiguring, disabling, and, occasionally, life-threatening clinical consequences. Advanced forms of lymphedema are readily diagnosed clinically, but more subtle presentations often require invasive imaging or other technologies for a conclusive diagnosis. On the other hand, lipedema, a chronic lymphatic microvascular disease with pathological accumulation of subcutaneous adipose tissue, is often misdiagnosed as obesity or lymphedema; currently there are no biomarkers or imaging criteria available for a conclusive diagnosis. Recent evidence suggests that otherwise-asymptomatic defective lymphatic vasculature likely contributes to an array of other pathologies, including obesity, inflammatory bowel disease, and neurological disorders. Accordingly, identification of biomarkers of lymphatic malfunction will provide a valuable resource for the diagnosis and clinical differentiation of lymphedema, lipedema, obesity, and other potential lymphatic pathologies. In this paper, we profiled and compared blood plasma exosomes isolated from mouse models and from human subjects with and without symptomatic lymphatic pathologies. We identified platelet factor 4 (PF4/CXCL4) as a biomarker that could be used to diagnose lymphatic vasculature dysfunction. Furthermore, we determined that PF4 levels in circulating blood plasma exosomes were also elevated in patients with lipedema, supporting current claims arguing that at least some of the underlying attributes of this disease are also the consequence of lymphatic defects., , Characterization of plasma-circulating exosomes from mouse models and patients with lymphatic dysfunction indicate that PF4 is a promising biomarker for the diagnosis of lymphatic disorders.

In recent years stem cell research has become increasingly important for regenerativemedicine and tissue engineering. The isolation of stem cells from adipose tissue evades ethicalconcerns with which embryonic stem cells and induces pluripotent stem cells (iPS) are afflicted,because of its declaration as clinical waste material. Tumescent liposuction is a minimallyinvasive procedure providing high amounts of adipose tissue rich in therapeutically relevantcells within a short time. The isolated stromal vascular fraction (SVF) and the adipose derivedstromal/stem cells (ASC) contained therein show a high regenerative potential and have beensuccessfully used in many clinical studies. Maintaining SVF cells in their natural environmentand therefore providing the maximum possible regenerative potential of adipose tissue-derivedcells is a prerequisite for successful autologous clinical application. With an improved gentleand fast isolation process by minor manipulation it is possible to obtain a therapeuticallyrelevant cell population. A physical stimulus already used in clinics is the extracorporealshockwave therapy (ESWT), shockwaves are characterized by their high rise in pressurewithin a very short time followed by cavitation wave with a negative amplitude. By applyinglow-energy ESWT on freshly obtained human liposuction material and isolated SVF cells (invitro) we aimed to equalize and enhance stem cell properties and their functionality. We wereable to show an increased adenosine tri-phosphate (ATP) concentration after applying ESWTon adipose tissue as well as a significantly increased expression of single mesenchymal andvascular surface markers in comparison with the untreated group. Additionally, the proteinsecretion of insulin-like growth factor 1 (IGF-1) and placental growth factor (PLGF) wassignificantly enhanced. Further it was investigated if there is the same beneficial effect whenapplying ESWT on the adipose tissue harvest site before liposuction to improve cell propertiesin situ. We showed a significantly enhanced viability, ATP concentration and populationdoublings after 3 weeks in culture for cells isolated from ESW treated adipose tissue harvestsite. Further the expression of mesenchymal and endothelial/pericytic markers was elevatedcollaborating with the increased angiogenic differentiation potential as well as the increasedsecretion of certain angiogenic proteins after ESWT in situ. Besides ESWT the effect of anotherphysical stimulus on SVF/ASC cells was tested - Low level laser therapy (LLLT) has alreadyshown beneficial effects. Therefore, we investigated effects of pulsed blue (475nm), green(516nm) and red (635nm) light from light-emitting diodes (LEDs) applied on freshly isolatedSVF cells. Cells had a stronger capacity to vascular tube formation after exposure to greenand red light concomitant with an increased concentration of vascular endothelial growth factor(VEGF) in the secretome. In a side project during the PhD program the hormone-relatedwomens disease lipedema was investigated. The SVF cell properties of healthy and lipedemapatients were investigated and a significant enhancement in cell yield as well as a reduction inadipogenic differentiation capacity of lipedema SVF cells was revealed. Within this workdifferent physical forces applied on adipose tissue and adipose tissue-derived cells werepresented as well as an improved isolation method and characteristics of degenerated adiposetissue. This are promising applications for the clinical use in the field of regenerative medicineand tissue regeneration.

The objective of the present study was to report that aggravating factors of lymphatic or venous edema contribute to aggravate the evolution of lymphedema. A 54-year-old women with a six-year history of venous thrombosis of the left leg reported that her family had thicker arms and legs and that she had inherited this genetic trait. Electrical bioimpedance analysis was performed with the In Body S10 device. The exam revealed total intracellular and extracellular water beyond the parameters of normality as well as water in the thorax and limbs. In the lower limbs, the total extracellular water/total body water ratio also surpassed the limits of normality. The findings demonstrated bilateral lower limb lymphedema with clinical signs in the left leg. Obesity can trigger a new concept of lymphedema that we denominate subclinical systemic lymphedema, which is characterized by an increase in body water. Moreover, aggravating processes of the venous system, such as deep vein thrombosis, can aggravate the edema.

Aim: The aim of the present study was to evaluate the prevalence of subclinical and clinical systemic lymphedema in patients with lipedema and different body mass index (BMI) values., Method: A cross-sectional study was conducted to determine the prevalence of subclinical systemic lymphedema and clinical lymphedema of the lower limbs detected by bioimpedance (InBody S10 device, Seoul, Korea) in 258 women with clinically diagnosed lipedema. The patients were divided into three groups based on BMI: Group I - BMI below 30 kg/m2; Group II - BMI between 30 and 40 kg/m2; and Group III - BMI 40 to 50 kg/m2., Results: Fisher's exact test revealed a statistically significant difference between Group I and both Groups II and III (p = 0.0001) regarding the occurrence of lower limb lymphedema., Conclusion: Patients with lipedema can develop edema even when their weight is within the standards of normality. However, obesity is an aggravating factor, as the prevalence of lipedema increases progressively with the increase in weight.

Summary Lipedema is a painful, chronically progressive disease that is characterized by a symmetrical increase in subcutaneous fat with fluid accumulation on the legs and / or arms. Due to ignorance of the clinical picture, the disease is often not recognized or misinterpreted. Correct diagnosis and treatment are important, however, as the prognosis of the disease can be influenced. A causal therapy for lipedema is not known because the exact etiology is not yet fully understood. A hereditary component is suspected on the basis of a family history of the disease. Since lipedema occurs almost exclusively in women and the onset of the disease is often associated with the onset of hormonal changes (puberty, pregnancy, menopause), In addition, the estrogen is assigned a decisive role in the development. In the present work we present an overview of the symptoms and clinical features of lipedema, its differential diagnoses, treatment options and, lastly, the current hypotheses on the pathogenesis of lipedema.

IN JUNE 2020, the Lipedema ICD-10-CM Committee, with support from the American Vein & Lymphatic Society (AVLS), submitted an application to the US Centers for Disease Control and Prevention to establish new ICD-10-CM codes for lipedema and lipolymphedema, two related adipose tissue disorders. Currently,

Patients with obesity-associated lipoedema minimize by diet only the regular fat especially in the lower leg area. The pathological lipoedema with a possible secondary lymphodynamic oedema remains and causes skin irritation, discomfort and pain wearing the compression elements. The dorsal lower leg lift with previous liposuction is a useful therapeutic strategy to overcome these difficulties. A 37-year-old female patient after post-bariatric surgery and massive weight loss (MWL) presented with a lower leg lipoedema and lymphodynamic oedema. She underwent a liposuction removing lipoedema of the lower leg followed by a calf lift procedure on both sides. With sufficient surgical experience in skin tightening surgery after MWL, a significant improvement in day-to-day problems in patients with lipoedema can be achieved by dorsal lift of the lower leg after liposuction.

Einleitung: Die Diagnostik des Lipödems basiert bislang auf rein klinischen Befunden, objektive Parameter fehlen bislang. Ziel dieser Studie ist es, einen möglichen Zusammen-hang zwischen einer standardisierten, sonographisch gemessenen Kompressibilität der subkutanen Fettschicht sowie dem Vergleich der Hautfettfalten an Abdomen und Oberschenkel und der klinischen Diagnose Lipödem aufzuzeigen. Material und Methode: Das Grundkollektiv zur Probandinnen-Auswahl bestand aus 1100 Patientinnen und Patienten. Davon wurden 1016 Patientinnen und Patienten wegen zutreffender Ausschlusskriterien ausgeschlossen. Die verbliebenen 84 Patientinnen wurden auf die klinische Diagnose „Lipödem der Beine“ untersucht. Die klinische Diagnose „Lipödem“ war bei 71 Patientinnen positiv und bei 13 Patientinnen negativ. Insgesamt haben drei Patientinnen die Teilnahme verweigert (eine mit negativer Diagnose, zwei mit positiver Diagnose); damit wurden 69 Patientinnen in der Gruppe der Lipödempatientinnen und zwölf Patientinnen in der Kontrollgruppe untersucht. Zudem wurden als weitere Kontrollgruppe sieben männliche „gesunde“ Probanden mit derselben Technik vermessen und verglichen. An Daten wurden für alle Probandinnen und Probanden das Alter, BMI, Verhältnis von Abdomen- zu Oberschenkelhautfettfalte (nur rechts), Subkutisdicke am Oberschenkel unkomprimiert und komprimiert auf beiden Seiten erhoben. Resultate: Die Annahme, dass die Subkutis bei Lipödempatientinnen deutlich geringer kompressierbar ist, konnte an 69 Lipödempatientinnen, die keinerlei Lymphödemsymptomatik zeigten, verifiziert werden. Die Kontrollgruppen (sieben Männer, zwölf Frauen) verhielten sich diesbezüglich negativ. Der Mittelwert dieser Kompressibilität lag in der Lipödemgruppe bei 7 %, in den Kontrollgruppen bei 22 % (Männer) bzw. 16 % (Frauen ohne Lipödem). Das Verhältnis der Hautfettfalten an Abdomen und Oberschenkel war bei Lipödempatientinnen mit im Mittel 0,43 signifikant unter den anderen Gruppen (Männer: 1,45; Frauen ohne Lipödem: 1,16). Diskussion: Die sonographisch gemessene Kompressibilität der Subkutis stellt einen wichtigen, objektiven Parameter zur Diagnostik des Lipödems dar. Eine zusätzliche positive Aussage liefert zudem der Vergleich der Hautfettfaltendicke an Abdomen und Oberschenkel mit statistisch signifikanten Unterschieden.

BACKGROUND: Although a large number of adult women worldwide are affected by lipedema, the physiologic conditions triggering onset and progression of this chronic disease remain enigmatic. In the present study, a descriptive epidemiologic situation of postoperative lipedema patients is presented. METHODS: The authors developed an online survey questionnaire for lipedema patients in Germany. The survey was conducted on 209 female patients who had been diagnosed with lipedema and had undergone tumescent liposuction. RESULTS: Most of the participants (average age, 38.5 years) had noticed a first manifestation of the disease at the age of 16. It took a mean of 15 years to accomplish diagnosis. Liposuction led to a significant reduction of pain, swelling, tenderness, and easy bruising as confirmed by the majority of patients. Hypothyroidism [n = 75 (35.9 percent) and depression [n = 48 (23.0 percent)] occurred at a frequency far beyond the average prevalence in the German population. The prevalence of diabetes type 1 [n = 3 (1.4 percent)], and diabetes type 2 [n = 2 (1 percent)] was particularly low among the respondents. Forty-seven of the lipedema patients (approximately 22.5 percent) suffered from a diagnosed migraine. Following liposuction, the frequency and/or intensity of migraine attacks became markedly reduced, as stated by 32 patients (68.1 percent). CONCLUSIONS: Quality of life increases significantly after surgery with a reduction of pain and swelling and decreased tendency to easy bruising. The high prevalence of hypothyroidism in lipedema patients could be related to the frequently observed lipedema-associated obesity. The low prevalence of diabetes, dyslipidemia, and hypertension appears to be a specific characteristic distinguishing lipedema from lifestyle-induced obesity.